ECYT -17% at low & closed -13% on news:
Endocyte Files Registration Statement With SEC for Proposed Public Offering of Common Stock
WEST LAFAYETTE, Ind., July 14, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT - News), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed underwritten public offering of 4,841,610 shares of its common stock. The Company is offering 4,000,000 shares and an existing institutional shareholder will sell the remaining shares. In addition, Endocyte has granted the underwriters the option to purchase up to 726,241 additional shares to cover over-allotments.
RBC Capital Markets, LLC and Leerink Swann LLC are acting as joint book-running managers, with Cowen and Company, LLC and Wedbush PacGrow Life Sciences acting as co-managers for the offering. This offering shall be made only by means of a prospectus. Once available, a preliminary prospectus relating to these securities may be obtained from RBC Capital Markets, LLC, Attention: Equity Syndicate, Three World Financial Center, 200 Vesey Street, 8th Floor, New York, NY 10281, or by telephone at 877-822-4089, or from Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by telephone at 800-808-7525, ext. 4814. The registration statement may be accessed through the SEC's website at www.sec.gov.
[Yahoo shows current market cap at around 357M] |
